NCT06133478 - Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

April 5, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

NUV001 active cohort 1

6 participants will be assigned to receive active treatment

DRUG

NUV001 active cohort 2

6 participants will be assigned to receive active treatment

DRUG

NUV001 active cohort 3

6 participants will be assigned to receive active treatment

DRUG

NUV001 active cohort 4

6 participants will be assigned to receive active treatment

DRUG

NUV001 placebo cohort 1

2 participants will be assigned to receive placebo

DRUG

NUV001 placebo cohort 2

2 participants will be assigned to receive placebo

DRUG

NUV001 placebo cohort 3

2 participants will be assigned to receive placebo

DRUG

NUV001 placebo cohort 4

2 participants will be assigned to receive placebo

Trial Locations (1)

Medpace Clinical Pharmacology Unit, Cincinnati